In this study, we examined the impact of BMI and serum apoB‐containing lipoproteins (remnant cholesterol and LDL‐C) on the efficacy of ICIs‐based therapy in treating NSCLC patients who were receiving ICIs for the first time, regardless of their PD‐L1 status. This evidence concerns the gene APOB and non-small cell lung carcinoma.